| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bong Ju Lee, Seung Ju Lee, Min Kyung Kim, Jung Goo Lee, Sung Woo Park, Gyung Mee Kim, Young Hoon Ki. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 11. issue 2. 2013-09-11. PMID:24023549. |
this study aimed to assess the efficacy of aripiprazole for the management of cognitive impairments and hyperprolactinemia in patients with schizophrenia on a stable dose of risperidone. |
2013-09-11 |
2023-08-12 |
Not clear |
| Yutaro Suzuki, Takuro Sugai, Naoki Fukui, Junzo Watanabe, Shin Ono, Nobuto Tsuneyama, Mami Saito, Toshiyuki Somey. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. Schizophrenia research. vol 145. issue 1-3. 2013-09-10. PMID:23375624. |
we examined the differences in plasma prl levels among 268 patients treated for schizophrenia with olanzapine (olz), risperidone (ris), aripiprazole (arp), quetiapine (qtp), or perospirone (per). |
2013-09-10 |
2023-08-12 |
human |
| Hiroshi Kimura, Nobuhisa Kanahara, Hiroyuki Watanabe, Masaomi Iy. Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophrenia research. vol 145. issue 1-3. 2013-09-10. PMID:23403411. |
potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. |
2013-09-10 |
2023-08-12 |
Not clear |
| B Almoguera, R Riveiro-Alvarez, J Lopez-Castroman, P Dorado, C Vaquero-Lorenzo, J Fernandez-Piqueras, A Llerena, F Abad-Santos, E Baca-García, R Dal-Ré, C Ayus. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. The pharmacogenomics journal. vol 13. issue 2. 2013-09-04. PMID:22212732. |
a series of 111 schizophrenia inpatients were genotyped for genetic variants previously associated with or potentially involved in risperidone response. |
2013-09-04 |
2023-08-12 |
Not clear |
| Keming Gao, Mary Mackle, Pilar Cazorla, Jun Zhao, Armin Szeged. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatric disease and treatment. vol 9. 2013-09-04. PMID:24003306. |
comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. |
2013-09-04 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Keishi Ge. The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Therapeutic advances in psychopharmacology. vol 2. issue 1. 2013-08-28. PMID:23983952. |
the influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. |
2013-08-28 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Keishi Ge. The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Therapeutic advances in psychopharmacology. vol 2. issue 1. 2013-08-28. PMID:23983952. |
this study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching schizophrenia patients from oral risperidone to risperidone long-acting injection (rlai) compared with a control group that continued receiving oral risperidone. |
2013-08-28 |
2023-08-12 |
Not clear |
| Ayşe Koroglu, Cicek Hocaogl. Risperidone-induced acromegaly: a case report. Therapeutic advances in psychopharmacology. vol 2. issue 2. 2013-08-28. PMID:23983960. |
in our study with a diagnosis of paranoid schizophrenia treated with risperidone for 14 years and operated with the diagnosis of pituitary macroadenoma, a 32-year-old female patient is presented in the light of the literature examining the framework of the history of disease. |
2013-08-28 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Yuichi Inoue, Keishi Ge. A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia. Therapeutic advances in psychopharmacology. vol 2. issue 6. 2013-08-28. PMID:23983981. |
a study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia. |
2013-08-28 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Yuichi Inoue, Keishi Ge. A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia. Therapeutic advances in psychopharmacology. vol 2. issue 6. 2013-08-28. PMID:23983981. |
we investigated the clinical efficacy and safety of switching to risperidone long-acting injection (rlai) in older patients with schizophrenia receiving oral risperidone. |
2013-08-28 |
2023-08-12 |
Not clear |
| O Castellano, M Arji, C Sancho, J Carro, A S Riolobos, V Molina, R Gómez-Nieto, José de Anchieta de Castro E Horta, M J Herrero-Turrión, D E Lópe. Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study. Behavioural brain research. vol 242. 2013-08-27. PMID:23291154. |
chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study. |
2013-08-27 |
2023-08-12 |
rat |
| O Castellano, M Arji, C Sancho, J Carro, A S Riolobos, V Molina, R Gómez-Nieto, José de Anchieta de Castro E Horta, M J Herrero-Turrión, D E Lópe. Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study. Behavioural brain research. vol 242. 2013-08-27. PMID:23291154. |
in the present work we analyzed the effect of the chronic administration of risperidone (2mg/kg over 65 days) on behavioural, morphological and molecular aspects in an experimental model of schizophrenia obtained by bilateral injection of ibotenic acid into the ventral hippocampus of new-born rats. |
2013-08-27 |
2023-08-12 |
rat |
| O Castellano, M Arji, C Sancho, J Carro, A S Riolobos, V Molina, R Gómez-Nieto, José de Anchieta de Castro E Horta, M J Herrero-Turrión, D E Lópe. Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study. Behavioural brain research. vol 242. 2013-08-27. PMID:23291154. |
it may be concluded that the administration of risperidone in the schizophrenia model employed helps to improve the altered functions, with no significant negative effects. |
2013-08-27 |
2023-08-12 |
rat |
| Amane Tateno, Ryosuke Arakawa, Masaki Okumura, Hajime Fukuta, Kazuyoshi Honjo, Keiichi Ishihara, Hiroshi Nakamura, Shin-ichiro Kumita, Yoshiro Okub. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia. Journal of clinical psychopharmacology. vol 33. issue 2. 2013-08-26. PMID:23422369. |
although double-blind clinical trials have demonstrated that blonanserin has equal efficacy to risperidone, and with a better profile especially with respect to prolactin elevation, its profile of in vivo receptor binding has not been investigated in patients with schizophrenia. |
2013-08-26 |
2023-08-12 |
human |
| Zhiyun Wei, Lei Wang, Tao Yu, Yang Wang, Liya Sun, Ti Wang, Ran Huo, Yang Li, Xi Wu, Shengying Qin, Yifeng Xu, Guoyin Feng, Lin He, Qinghe Xin. Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy. Journal of clinical psychopharmacology. vol 33. issue 2. 2013-08-26. PMID:23422377. |
we genotyped 5 tag-single nucleotide polymorphisms of the hrh4 gene and analyzed their association with the reduction in positive and negative syndrome scale (panss) scores in a group of 113 chinese han patients with schizophrenia who were following an 8-week period of risperidone monotherapy. |
2013-08-26 |
2023-08-12 |
human |
| Zhiyun Wei, Lei Wang, Tao Yu, Yang Wang, Liya Sun, Ti Wang, Ran Huo, Yang Li, Xi Wu, Shengying Qin, Yifeng Xu, Guoyin Feng, Lin He, Qinghe Xin. Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy. Journal of clinical psychopharmacology. vol 33. issue 2. 2013-08-26. PMID:23422377. |
our results provide the first evidence that an hrh4 polymorphism may be a molecular marker for the prediction of risperidone efficacy and suggest novel pharmacologic links between hrh4 gene and treatment of schizophrenia. |
2013-08-26 |
2023-08-12 |
human |
| Mohammad-Reza Khodaie-Ardakani, Sahar Seddighi, Amirhossein Modabbernia, Farzin Rezaei, Bahman Salehi, Mandana Ashrafi, Narges Shams-Alizadeh, Maryam Mohammad-Karimi, Gholam-Reza Esfandiari, Reza Hajiaghaee, Shahin Akhondzade. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Journal of psychiatric research. vol 47. issue 4. 2013-08-21. PMID:23375406. |
granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. |
2013-08-21 |
2023-08-12 |
Not clear |
| Mohammad-Reza Khodaie-Ardakani, Sahar Seddighi, Amirhossein Modabbernia, Farzin Rezaei, Bahman Salehi, Mandana Ashrafi, Narges Shams-Alizadeh, Maryam Mohammad-Karimi, Gholam-Reza Esfandiari, Reza Hajiaghaee, Shahin Akhondzade. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Journal of psychiatric research. vol 47. issue 4. 2013-08-21. PMID:23375406. |
in a randomized, double-blind, and placebo-controlled study, forty stable patients with schizophrenia (dsm-iv-tr), were randomized to either granisetron (1 mg twice daily) or placebo (twice daily) in addition to risperidone up to 6 mg/day for eight weeks. |
2013-08-21 |
2023-08-12 |
Not clear |
| Gerhard Gross, Karsten Wicke, Karla U Dresche. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Naunyn-Schmiedeberg's archives of pharmacology. vol 386. issue 2. 2013-07-30. PMID:23128852. |
despite considerable affinity for d(3) receptors, the second-generation antipsychotics clozapine, risperidone, and olanzapine when administered to patients with schizophrenia seem not to occupy d(3) receptors sufficiently to derive any conclusion on a d(3)-mediated therapeutic benefit. |
2013-07-30 |
2023-08-12 |
Not clear |
| Silvio Cacci. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatric drugs. vol 15. issue 3. 2013-07-30. PMID:23588704. |
recent controlled trials have demonstrated the efficacy of some of these agents (including aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) in adolescent schizophrenia and children or adolescent bipolar mania, or to treat severe aggression and self-injury in the context of autism in children and adolescents. |
2013-07-30 |
2023-08-12 |
Not clear |